In short
TALADEGIB (also known as LY2940680 or ENV-101) is an investigational drug currently being studied in various clinical trials for treating advanced cancers and idiopathic pulmonary fibrosis (IPF). As a potent Hedgehog (Hh) pathway inhibitor, TALADEGIB works by blocking specific enzymes that cancer cells need to grow and divide. Clinical trials are evaluating TALADEGIB both alone and in combination with other anticancer agents to determine its safety, effectiveness, and optimal dosing. These studies involve patients with various types of advanced solid tumors, including those with specific genetic mutations, as well as patients with lung conditions like IPF. This article provides an overview of the current clinical research involving TALADEGIB.
Key points
- TALADEGIB (also known as LY2940680 or ENV-101) is an investigational drug that inhibits the Hedgehog signaling pathway, which plays a role in cell growth and tumor development. Clinical trials are evaluating its safety and effectiveness for various advanced cancers, including those with specific genetic mutations like PTCH1 loss-of-function, as well as for idiopathic pulmonary fibrosis (IPF). The drug is administered orally at doses typically ranging from 100-400 mg daily and is being studied both alone and in combination with other treatments such as chemotherapy and radiation. Research is measuring outcomes like tumor response rates, survival, lung function changes, and side effects to determine optimal dosing and identify which patients might benefit most from this targeted therapy.
At a glance
- Drug Names
- TALADEGIB (also known as LY2940680, ENV-101)
- Mechanism of Action
- Hedgehog (Hh) pathway inhibitor that blocks the smoothened (Smo) protein
- Conditions Studied
- - Advanced solid tumors; - Solid tumors with PTCH1 loss-of-function mutations; - Small cell lung carcinoma; - Idiopathic pulmonary fibrosis (IPF); - Medulloblastoma in children; - Rhabdomyosarcoma; - Esophageal and gastroesophageal junction adenocarcinoma
- Dosage Ranges
- - Adults: 50-600 mg orally once daily; - Children: Doses based on body surface area (up to 370 mg/m²); - Most common adult doses tested: 100 mg, 200 mg, 300 mg, 400 mg
- Administration
- Oral tablets or capsules taken once daily
- Combination Therapies
- - With carboplatin and etoposide for small cell lung cancer; - With paclitaxel, carboplatin, and radiation for esophageal cancer; - With LY3039478 (another cancer drug); - Interaction studies with nintedanib for IPF
- Primary Outcomes Measured
- - Maximum tolerated dose (MTD); - Safety profile and adverse events; - Objective response rate (ORR); - Progression-free survival (PFS); - Changes in lung function for IPF studies
- Secondary Measurements
- - Pharmacokinetics (Cmax, Tmax, AUC); - Clinical benefit rate (CBR); - Overall survival (OS); - Duration of response (DOR); - Gli1 inhibition (marker of drug activity); - Patient-reported outcomes for IPF
- Safety Monitoring
- - Non-hematological toxicities; - Hematological toxicities; - Vital signs; - Laboratory abnormalities; - Hospitalizations
- Trial Phases
- Phase 1, Phase 1b, Phase 2 trials (no Phase 3 trials reported)
- Special Populations
- - Adults with advanced cancers; - Pediatric patients with medulloblastoma or rhabdomyosarcoma; - Japanese patients with advanced cancers; - Patients with IPF
What is Taladegib?
Taladegib (also known as LY2940680 or ENV-101) is an investigational anti-cancer medication that belongs to a class of drugs called Hedgehog pathway inhibitors . It is being studied for the treatment of various types of cancer and other conditions such as idiopathic pulmonary fibrosis. Taladegib is not yet approved by regulatory agencies for regular clinical use but is being evaluated in multiple clinical trials to assess its safety and effectiveness.
Taladegib is administered orally in the form of tablets or capsules, which makes it convenient for patients as it doesn't require hospital visits for intravenous administration . The medication is currently only available to patients participating in clinical trials.
How Taladegib Works
Taladegib works by targeting and inhibiting a specific cellular pathway called the Hedgehog (Hh) signaling pathway . This pathway plays an important role in embryonic development but can become abnormally activated in certain cancers, contributing to tumor growth.
More specifically, taladegib is a potent inhibitor of a protein called Smoothened (Smo), which is a key component of the Hedgehog pathway. By blocking Smoothened, taladegib prevents the activation of Gli1, a transcription factor that, when activated, turns on genes involved in cell growth and survival . Scientists can measure the level of Gli1 inhibition in skin biopsies to determine if taladegib is effectively blocking the Hedgehog pathway in patients.
In certain cancers, especially those with mutations in a gene called PTCH1 (Patched-1), the Hedgehog pathway becomes continuously activated. PTCH1 normally functions as a negative regulator of the pathway, and when it has loss-of-function mutations, the pathway becomes overactive, potentially contributing to cancer development . Taladegib may be particularly effective in cancers with these specific genetic alterations.
Conditions Treated with Taladegib
Based on clinical trials data, taladegib is being investigated for several medical conditions:
Cancer Types
- Advanced Solid Tumors: Taladegib is being studied in patients with various types of advanced solid tumors, particularly those with specific genetic mutations in the PTCH1 gene .
- Basal Cell Carcinoma (BCC): This is a type of skin cancer where the Hedgehog pathway is often abnormally activated .
- Medulloblastoma: A type of brain cancer that occurs mainly in children and sometimes involves Hedgehog pathway activation .
- Rhabdomyosarcoma: A type of cancer that develops from skeletal muscle cells, most common in children .
- Small Cell Lung Cancer: Taladegib has been studied in combination with chemotherapy drugs (carboplatin and etoposide) for this aggressive form of lung cancer .
- Esophageal and Gastroesophageal Junction Adenocarcinoma: Taladegib is being investigated in combination with chemotherapy and radiation therapy for these cancers .
Non-Cancer Conditions
- Idiopathic Pulmonary Fibrosis (IPF): This is a chronic, progressive lung disease characterized by scarring of lung tissue. Taladegib is being evaluated for its potential to help patients with IPF .
Dosage and Administration
As taladegib is still in clinical trials, the optimal dosage has not been definitively established. However, from the clinical trials data, several dosage regimens have been studied:
- For advanced solid tumors: Doses ranging from 50 mg to 600 mg once daily have been studied, with 200 mg and 300 mg once daily being common doses in recent trials .
- For idiopathic pulmonary fibrosis: A dose of 200 mg once daily has been studied .
- For pediatric cancers: Dosages based on body surface area have been used, ranging from 23 mg/m² to 370 mg/m² once daily .
Taladegib is taken orally, typically once daily, with treatment cycles usually lasting 28 days. In some clinical trials, taladegib is administered in combination with other cancer treatments such as chemotherapy or radiation therapy .
Clinical Studies of Taladegib
Taladegib has been evaluated in multiple clinical trials to assess its safety, effectiveness, and proper dosing:
Phase 1 Studies
Initial studies focused on determining the safety, tolerability, and proper dosage of taladegib in patients with advanced cancers. These studies found that taladegib could be administered at doses up to 600 mg daily, with the most common side effects being manageable .
A study in Japanese patients with advanced solid tumors evaluated doses of 100 mg, 200 mg, and 400 mg daily and found that taladegib was generally well-tolerated in this population .
Another study investigated how taladegib is processed by the body (pharmacokinetics) in healthy volunteers, finding that most of the drug is eliminated through feces .
Phase 2 Studies
More recent studies have focused on specific patient populations:
- A study is evaluating taladegib at doses of 200 mg and 300 mg once daily in patients with advanced solid tumors that have specific mutations in the PTCH1 gene .
- Another study is assessing taladegib at a dose of 200 mg once daily in patients with idiopathic pulmonary fibrosis .
- Taladegib is also being studied in combination with other cancer treatments, such as chemotherapy and radiation therapy, for esophageal and gastroesophageal junction cancers .
Pediatric Studies
A study specifically focused on children with medulloblastoma or rhabdomyosarcoma that has returned or doesn't respond to initial treatment is evaluating taladegib at various dosages based on body surface area .
Potential Side Effects
While taladegib is still being studied and the full profile of side effects is not completely characterized, some potential side effects have been observed in clinical trials:
- Hair loss (alopecia): This is a common side effect of Hedgehog pathway inhibitors .
- Fatigue: Feeling tired or exhausted is commonly reported .
- Gastrointestinal symptoms: These may include nausea, vomiting, constipation, or diarrhea .
- Decreased appetite: Some patients experience reduced desire to eat .
- Liver enzyme elevations: Temporary increases in liver enzymes have been observed in some patients .
- Blood count changes: These may include decreases in certain types of blood cells, which could potentially increase the risk of infection, bleeding, or fatigue .
The severity and frequency of these side effects may depend on the dose of taladegib, whether it's used alone or in combination with other treatments, and individual patient factors .
Drug Interactions
Limited information is available about potential drug interactions with taladegib as it is still in clinical development. However, some studies have specifically examined potential interactions:
- A study is investigating the potential interaction between taladegib and nintedanib (a medication used to treat idiopathic pulmonary fibrosis) .
- Another study evaluated the effects of food and a proton pump inhibitor (a type of medication that reduces stomach acid) on how taladegib is absorbed by the body .
- Taladegib has also been studied in combination with other cancer drugs, including LY3039478 (a Notch inhibitor), suggesting these medications can be used together .
As with any medication, it's important for patients in clinical trials to inform their healthcare providers about all medications, supplements, and herbal products they are taking to avoid potential harmful interactions.
Ongoing Research and Future Directions
Research on taladegib continues to evolve, with several ongoing clinical trials exploring its potential in different conditions and in combination with other treatments:
- A Phase 2 study is evaluating taladegib in patients with advanced solid tumors that have specific mutations in the PTCH1 gene, which may help identify which patients are most likely to benefit from this treatment .
- Taladegib is being investigated for idiopathic pulmonary fibrosis, which represents a potential expansion beyond cancer treatment .
- Studies are exploring taladegib in combination with chemotherapy and radiation therapy for various cancers, which may enhance its effectiveness .
- Research is ongoing to better understand how taladegib interacts with other medications, which will help guide its safe use if it receives regulatory approval .
The results of these ongoing studies will provide more information about the safety and effectiveness of taladegib and help determine which patients are most likely to benefit from this treatment.
If you are interested in learning more about taladegib or are considering participating in a clinical trial, it's important to discuss this with your healthcare provider, who can provide personalized information based on your specific medical condition and circumstances.